SCHEMBL26628779

SCHEMBL26628779

COC(=O)c1cc(OC)c(NC2CCOCC2)cc1N

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.56
ALDH1A1 P00352 5/20 0.48
HSD17B10 Q99714 4/20 0.46
HPGD P15428 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
PLK4 O00444 1/20 0.43
POLB P06746 1/20 0.43
GAA P10253 2/20 0.42
CFTR P13569 1/20 0.41
YAP1 P46937 1/20 0.41
MAPT P10636 2/20 0.39
OPRK1 P41145 1/20 0.39
TSHR P16473 1/20 0.39
MAPK1 P28482 1/20 0.39
GAK O14976 1/20 0.39
GLA P06280 1/20 0.38
CASP1 P29466 1/20 0.38
CASP7 P55210 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26628823 0.81 NPSR1 (0.47) KDM4EALDH1A1HSD17B10HPGDSMN1; SMN2
SCHEMBL29734702 0.81 NPSR1 (0.47) KDM4EALDH1A1HSD17B10HPGDSMN1; SMN2
SCHEMBL12316332 0.79 HTT (0.53) KDM4EALDH1A1HSD17B10HPGDSMN1; SMN2
SCHEMBL24735855 0.78 KDM4E (0.61) KDM4EALDH1A1HSD17B10HPGDSMN1; SMN2
SCHEMBL29940033 0.78 KDM4E (0.61) KDM4EALDH1A1HSD17B10HPGDSMN1; SMN2
SCHEMBL24735678 0.78 KDM4E (0.61) KDM4EALDH1A1HSD17B10HPGDSMN1; SMN2
SCHEMBL28779898 0.77 KDM4E (0.45) KDM4EALDH1A1HSD17B10HPGDPLK4
SCHEMBL28779894 0.77 KDM4E (0.45) KDM4EALDH1A1HSD17B10HPGDPLK4
SCHEMBL23901206 0.76 OPRK1 (0.46) KDM4EALDH1A1HSD17B10HPGDSMN1; SMN2
SCHEMBL28999518 0.76 KDM4E (0.58) KDM4EALDH1A1HSD17B10HPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240067613-A1 NOVEL QUINAZOLINE DERIVATIVES AS SOS1 INHIBITORS AND USE THEREOF HANMI PHARMACEUTICAL CO., LTD. (KR) 2024-02-29 US disclosed
US-20240067613-A1 NOVEL QUINAZOLINE DERIVATIVES AS SOS1 INHIBITORS AND USE THEREOF HANMI PHARMACEUTICAL CO., LTD. (KR) 2024-02-29 US disclosed
US-20240067613-A1 NOVEL QUINAZOLINE DERIVATIVES AS SOS1 INHIBITORS AND USE THEREOF HANMI PHARMACEUTICAL CO., LTD. (KR) 2024-02-29 US disclosed
EP-4269395-A1 NOVEL QUINAZOLINE DERIVATIVE COMPOUND AS SOS1 INHIBITOR, AND USE THEREOF Hanmi Pharmaceutical Co., Ltd. (KR) 2023-11-01 EP disclosed
EP-4269395-A1 NOVEL QUINAZOLINE DERIVATIVE COMPOUND AS SOS1 INHIBITOR, AND USE THEREOF Hanmi Pharmaceutical Co., Ltd. (KR) 2023-11-01 EP disclosed
WO-2022139304-A1 NOVEL QUINAZOLINE DERIVATIVE COMPOUND AS SOS1 INHIBITOR, AND USE THEREOF 한미약품 주식회사 2022-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240067613-A1 NOVEL QUINAZOLINE DERIVATIVES AS SOS1 INHIBITORS AND USE THEREOF SOS1, RASGRP1, RAC1 KDM4E 4163/4885ALDH1A1 3440/4885HSD17B10 4729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.